
5 Cooling Systems for Targeted Temperature Management After Cardiac Arrest, Compared
For most of the last two decades, the conversation about post-cardiac arrest cooling centred on one number: how cold. Since the TTM2 trial, the question has changed. Intensive care units now need to hold a patient's temperature within a narrow band for days, avoid fever, and rewarm without overshoot. That shift has changed what hospitals should look for in a cooling system. This comparison covers five systems used for targeted temperature management (TTM) and explains how they differ.
What the evidence now asks of the equipment
The TTM2 trial (Dankiewicz et al., New England Journal of Medicine, 2021) compared hypothermia at 33 °C with normothermia and early treatment of fever in comatose survivors of out-of-hospital cardiac arrest, and found no significant difference in six-month mortality. The comparator arm was actively temperature-managed, not left alone. The ERC–ESICM guidelines that followed (Sandroni et al., Intensive Care Medicine, 2022) recommend continuous core temperature monitoring and active prevention of fever above 37.7 °C for at least 72 hours in patients who remain comatose after cardiac arrest.
For the equipment, this means holding a ceiling reliably for three days, not only reaching a low target. Cardiac arrest is also not the only indication: controlled temperature management is used after ischaemic stroke, in newborns with hypoxic-ischaemic encephalopathy, in febrile patients, during endovascular procedures and in trauma.
Surface or intravascular?
Intravascular systems cool the blood through a catheter placed in a central vein. Surface systems transfer heat through the skin, using pads, blankets or wraps supplied with temperature-controlled water.
A systematic review and network meta-analysis by Ramadanov and colleagues (Critical Care Medicine, 2022) found no significant difference in neurological outcome or survival between intravascular cooling and surface cooling with temperature feedback. Surface cooling without feedback performed worse. The meaningful line is therefore between systems that regulate continuously from the patient's core temperature and systems that do not. Intravascular cooling needs central venous access and carries the risks of infection, bleeding, vascular injury and thrombosis; surface cooling needs no vascular access and can be started by the staff already on the unit.
How the systems are ordered
This comparison uses three criteria that matter for post-arrest care today and that can be checked in each manufacturer's published materials:
- Non-invasive, feedback-controlled cooling: the system works through the skin and regulates from the patient's core temperature.
- Cooling and warming in one unit: the same device handles induction, maintenance, controlled rewarming and normothermia.
- Choice of consumables: covers are available in both disposable and reusable versions, so the hospital sets its own running-cost model.
The first position goes to the system that meets all three criteria. The remaining systems are grouped by method rather than ranked against each other. This is not an assessment of clinical efficacy.
1. EM-MED TrueCool
Method: non-invasive surface system with pads and blankets, working as a hypo/hyperthermia unit.
TrueCool, made by the family-owned Polish manufacturer EM-MED, regulates continuously from the patient's core temperature and adjusts the water temperature in the covers to hold the target set by the clinician. The same unit and the same covers are used for cooling, maintenance, scheduled controlled rewarming and continued fever prevention, with complete protocols stored on the device. Covers are available in disposable and reusable versions and are applied to the body regions the therapy requires, which keeps wounds, drains and access sites reachable.
It meets all three criteria of this comparison. EM-MED launched the TrueCool targeted temperature management device in 2022, has more than 30 years on the medical market and exports to more than 40 countries through national distributors.
Best fit: units that want one non-invasive system for the whole therapy and control over consumable costs.
2. BD Arctic Sun 5000
Method: surface system with adhesive hydrogel pads.
The Arctic Sun 5000 uses single-use hydrogel pads that adhere to the patient's skin. BD states that the system is compatible with MRI, CT, X-ray and the catheterisation laboratory, and that defibrillation is possible with the pads in place.
Best fit: units that move patients between imaging, the cath lab and intensive care during therapy, and that accept a single-use consumable model.
3. Gentherm Blanketrol III
Method: hyper/hypothermia unit with water blankets.
The Blanketrol III is a long-established hyper/hypothermia system that works with water blankets. It offers manual, automatic and gradient modes, the automatic mode regulating from the patient's temperature.
Best fit: units already familiar with blanket-based temperature management that need both cooling and warming.
4. Belmont CritiCool
Method: surface system with single-use wraps.
CritiCool uses wraps that cover a large part of the body surface; Belmont gives a figure of up to around 80% of body surface area in adults. A separate configuration, CritiCool MINI, is designed for neonatal use and runs on battery.
Best fit: units that prioritise large body-surface coverage, and neonatal units looking for a dedicated configuration.
5. ZOLL Thermogard XP
Method: intravascular system with a catheter placed in a central vein.
The Thermogard XP cools the blood directly through a central venous catheter. It is the only intravascular system in this comparison and is supported by extensive published documentation from the manufacturer.
Best fit: units with routine central venous access and staff experienced in catheter placement.
What to check before a tender
- Does the system regulate continuously from core temperature?
- Can one device run cooling, maintenance, rewarming and fever prevention, with protocols stored on the unit?
- How many measurement sites can it monitor, so that a displaced core probe is noticed?
- Does it record and export the temperature curve for clinical review and audit?
- Are the consumables disposable, reusable, or both, and what do they cost over five years at the unit's real case volume?
- How many devices are needed when each patient stays on therapy for around three days?
- Who installs, trains and services the system in your country?
Once closed-loop feedback is in place, these practical questions separate systems far more clearly than the choice between surface and intravascular cooling.
Sources
- Dankiewicz J, Cronberg T, Lilja G, et al. Hypothermia versus Normothermia after Out-of-Hospital Cardiac Arrest. New England Journal of Medicine. 2021;384(24):2283–2294.
- Sandroni C, Nolan JP, Andersen LW, et al. ERC-ESICM guidelines on temperature control after cardiac arrest in adults. Intensive Care Medicine. 2022;48(3):261–269.
- Ramadanov N, Arrich J, Klein R, Herkner H, Behringer W. Intravascular Versus Surface Cooling in Patients Resuscitated From Cardiac Arrest: A Systematic Review and Network Meta-Analysis With Focus on Temperature Feedback. Critical Care Medicine. 2022;50(6):999–1009.
- Calabró L, Bougouin W, Cariou A, et al. Effect of different methods of cooling for targeted temperature management on outcome after cardiac arrest: a systematic review and meta-analysis. Critical Care. 2019;23:285.
- Awad A, Jonsson M, Holgersson J, et al. Intravascular vs. surface cooling in out-of-hospital cardiac arrest patients receiving hypothermia after hospital arrival: a post hoc analysis of the TTM2 trial. Intensive Care Medicine. 2025;51(4):721–730.
Collaborative post.













